论文部分内容阅读
目的研究恩替卡韦辅助治疗乙肝肝硬化失代偿期的临床效果。方法随机选取2012年4月—2014年4月该院收治的70例乙型肝炎肝硬化失代偿期患者为研究对象,将其随机分为观察组和对照组,对照组采用常规对症治疗,观察组在常规治疗基础上,采用恩替卡韦辅助治疗,比较两组患者治疗效果。结果观察组HBV-DNA转阴率明显高于对照组,且死亡率比对照组低,差异有统计学意义(χ2=8.548,P<0.05)。结论恩替卡韦辅助治疗乙型肝炎引起的肝硬化失代偿期患者,能有效降低肝硬化失代偿期死亡率,疗效显著,具有临床推广价值。
Objective To study the clinical efficacy of entecavir in the treatment of decompensated liver cirrhosis. Methods A total of 70 patients with decompensated hepatitis B cirrhosis admitted from April 2012 to April 2014 in our hospital were selected randomly as study subjects and randomly divided into observation group and control group. The control group was treated with conventional symptomatic treatment, Observation group based on conventional treatment, the use of entecavir adjuvant therapy, the treatment effect of two groups were compared. Results The negative rate of HBV-DNA in the observation group was significantly higher than that in the control group, and the mortality rate was lower than that in the control group (χ2 = 8.548, P <0.05). Conclusion Entecavir adjuvant treatment of hepatitis B-induced cirrhosis patients with decompensated liver cirrhosis can effectively reduce the mortality rate, significant effect, with clinical value.